Addition of pamidronate to chemotherapy for the treatment of osteosarcoma

Paul A. Meyers, John H. Healey, Alexander J. Chou, Leonard H. Wexler, Pamela R. Merola, Carol D. Morris, Michael P. Laquaglia, Michael G. Kellick, Sara J. Abramson, Richard Gorlick

Research output: Contribution to journalArticlepeer-review

147 Scopus citations


Background: This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma. Methods: The authors treated 40 patients with osteosarcoma with cisplatin, doxorubicin, and methotrexate with the addition of pamidronate 2 mg/kg/dose (max dose 90 mg) monthly for 12 doses. Survival, event-free survival (EFS), and durability of orthopedic reconstruction were evaluated. Results: For patients with localized disease, event-free survival (EFS) at 5 years was 72% and overall survival 93%. For patients with metastatic disease, EFS at 5 years was 45% and overall survival 64%. Toxicity was similar to patients treated with chemotherapy alone. Thirteen of 14 uncemented implants demonstrated successful osteointegration. Among allograft reconstructions, there were 2 graft failures, 4 delayed unions, and 6 successful grafts. Overall, 5 of 33 reconstructions failed. There were no stress fractures or growth disturbances. Conclusions: Pamidronate can be safely incorporated with chemotherapy for the treatment of osteosarcoma. It does not impair the efficacy of chemotherapy. Pamidronate may improve the durability of limb reconstruction.

Original languageEnglish (US)
Pages (from-to)1736-1744
Number of pages9
Issue number8
StatePublished - Apr 15 2011


  • bisphosphonates
  • chemotherapy
  • endoprosthetic reconstruction
  • limb-sparing surgery
  • osteosarcoma
  • pamidronate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Addition of pamidronate to chemotherapy for the treatment of osteosarcoma'. Together they form a unique fingerprint.

Cite this